A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients With DSM-IV-TR Schizophrenia.
Phase of Trial: Phase III
Latest Information Update: 01 Dec 2015
At a glance
- Drugs Pomaglumetad methionil (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 29 Aug 2012 Status changed from recruiting to discontinued, according to an Eli Lilly media release.
- 27 Apr 2012 Planned patient number changed from 950 to 1100 as reported by ClinicalTrials.gov.